Gell Pharmaceuticals gets $2.5 mil. to develop cocaine addiction treatments from the Abell Foundation.
Executive Summary
GELL PHARMACEUTICALS GETS $2.5 MIL. TO DEVELOP COCAINE ADDICTION TREATMENTS from the Abell Foundation, a Baltimore philanthropic organization affiliated with the family that publishes the Baltimore Sun newspapers. The $2.5 mil. will provide start-up funds for GELL, which is 20% owned by Baltimore-based Guilford Pharmaceuticals and 80% owned by Abell. GELL will attempt to develop a compound to treat cocaine addiction based on research conducted at Johns Hopkins University and the National Institute on Drug Abuse of the National Institutes of Health.